What is HC Wainwright's Forecast for Immunovant Q2 Earnings?

Key Points

• HC Wainwright lowered their Q2 2026 earnings estimate for Immunovant to ($0.79) per share, down from a previous forecast of ($0.76).
• The consensus rating for Immunovant's stock remains a "Moderate Buy" with a price target of $35.20 from various analysts.
• Immunovant's stock recently traded at $15.32, with a market capitalization of $2.67 billion.

Immunovant, Inc. (NASDAQ:IMVT - Free Report) - Equities research analysts at HC Wainwright cut their Q2 2026 earnings per share (EPS) estimates for Immunovant in a report released on Tuesday, August 12th. HC Wainwright analyst D. Tsao now forecasts that the company will earn ($0.79) per share for the quarter, down from their prior forecast of ($0.76). The consensus estimate for Immunovant's current full-year earnings is ($2.69) per share. HC Wainwright also issued estimates for Immunovant's Q3 2026 earnings at ($0.83) EPS, Q4 2026 earnings at ($0.88) EPS, FY2026 earnings at ($3.24) EPS, Q1 2027 earnings at ($0.91) EPS, Q2 2027 earnings at ($0.95) EPS, Q3 2027 earnings at ($0.96) EPS, Q4 2027 earnings at ($0.92) EPS, FY2027 earnings at ($3.73) EPS, FY2028 earnings at ($3.60) EPS, FY2029 earnings at ($0.55) EPS and FY2030 earnings at $2.69 EPS.

Immunovant (NASDAQ:IMVT - Get Free Report) last released its earnings results on Monday, August 11th. The company reported ($0.60) EPS for the quarter, beating analysts' consensus estimates of ($0.69) by $0.09. During the same period in the prior year, the firm posted ($0.60) earnings per share.

Several other research firms have also issued reports on IMVT. The Goldman Sachs Group upgraded shares of Immunovant to a "hold" rating and set a $18.00 price target for the company in a research report on Thursday, July 10th. Citigroup restated a "buy" rating on shares of Immunovant in a research report on Monday, August 11th. Bank of America cut their price target on shares of Immunovant from $33.00 to $30.00 and set a "buy" rating for the company in a research report on Tuesday, August 12th. UBS Group upped their price target on shares of Immunovant from $17.00 to $18.00 and gave the company a "neutral" rating in a research report on Monday, July 28th. Finally, JPMorgan Chase & Co. cut their price target on shares of Immunovant from $40.00 to $37.00 and set an "overweight" rating for the company in a research report on Tuesday, August 12th. Three analysts have rated the stock with a hold rating, eight have given a buy rating and one has issued a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and a consensus price target of $35.20.

Immunovant Stock Performance

NASDAQ IMVT traded up $0.02 during trading on Thursday, hitting $15.22. 1,781,359 shares of the company's stock traded hands, compared to its average volume of 1,321,870. The stock has a fifty day moving average of $16.50 and a two-hundred day moving average of $16.90. Immunovant has a 12-month low of $12.72 and a 12-month high of $34.47.

Institutional Trading of Immunovant

Several institutional investors and hedge funds have recently bought and sold shares of the stock. Vanguard Group Inc. lifted its holdings in Immunovant by 3.9% in the first quarter. Vanguard Group Inc. now owns 6,936,859 shares of the company's stock worth $118,551,000 after buying an additional 257,445 shares during the period. Deep Track Capital LP lifted its holdings in Immunovant by 38.0% in the fourth quarter. Deep Track Capital LP now owns 6,000,000 shares of the company's stock worth $148,620,000 after buying an additional 1,652,536 shares during the period. T. Rowe Price Investment Management Inc. lifted its holdings in Immunovant by 15.2% in the first quarter. T. Rowe Price Investment Management Inc. now owns 5,894,824 shares of the company's stock worth $100,743,000 after buying an additional 777,590 shares during the period. Baker BROS. Advisors LP lifted its holdings in Immunovant by 219.6% in the first quarter. Baker BROS. Advisors LP now owns 5,457,881 shares of the company's stock worth $93,275,000 after buying an additional 3,750,000 shares during the period. Finally, Alpine Global Management LLC lifted its holdings in Immunovant by 21.7% in the first quarter. Alpine Global Management LLC now owns 2,626,692 shares of the company's stock worth $44,890,000 after buying an additional 467,788 shares during the period. 47.08% of the stock is currently owned by hedge funds and other institutional investors.

Insider Transactions at Immunovant

In other Immunovant news, insider Michael Geffner sold 2,385 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The shares were sold at an average price of $18.15, for a total value of $43,287.75. Following the completion of the sale, the insider directly owned 221,825 shares in the company, valued at $4,026,123.75. This trade represents a 1.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available at this link. Also, CTO Jay S. Stout sold 2,805 shares of the firm's stock in a transaction dated Wednesday, July 23rd. The stock was sold at an average price of $18.15, for a total transaction of $50,910.75. Following the completion of the sale, the chief technology officer owned 204,919 shares of the company's stock, valued at $3,719,279.85. This trade represents a 1.35% decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 7,869 shares of company stock valued at $140,384. 1.80% of the stock is currently owned by company insiders.

Immunovant Company Profile

Immunovant, Inc, a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops batoclimab, a novel fully human monoclonal antibody that target the neonatal fragment crystallizable receptor for the treatment of myasthenia gravis, thyroid eye disease, chronic inflammatory demyelinating polyneuropathy, and Graves diseases, as well as warm autoimmune hemolytic anemia.